Canaccord lowered the firm’s price target on Health Catalyst to $14 from $16 and keeps a Buy rating on the shares. The firm updated its estimates following its Q2 results and noted Health Catalyst has posted solid financial performance versus guidance and our estimates considering the continued tough operating environment for health systems, although there have been signs of improving operating margins in the health system end market.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HCAT:
- Health Catalyst reports Q2 adjusted EPS 5c, consensus 0c
- Health Catalyst Reports Second Quarter 2023 Results
- Goldman Sachs upgraded, Rivian downgraded: Wall Street’s top analyst calls
- Health Catalyst initiated with an Overweight at Cantor Fitzgerald
- Health Catalyst to Announce Second Quarter 2023 Operating Results and Host Conference Call on Tuesday, August 8, 2023